drugset
drugset / Trial / NCT04060173

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

NCT04060173 ↗

Phase 1 Completed 27 enrolled Atom Therapeutics Co., Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.

Timeline

Start
2019-09-05
Primary completion
2019-12-29
Completion
2020-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ABP-671 Unknown — Oral

Indications

gout